X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (399) 399
Publication (83) 83
Patent (17) 17
Book Chapter (9) 9
Conference Proceeding (4) 4
Book Review (2) 2
Web Resource (2) 2
Book / eBook (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (206) 206
oncology (125) 125
index medicus (123) 123
hematology (84) 84
article (57) 57
apoptosis (55) 55
female (53) 53
male (51) 51
chronic lymphocytic-leukemia (47) 47
apoptosis - drug effects (46) 46
adult (44) 44
antineoplastic agents - pharmacology (44) 44
middle aged (43) 43
aged (42) 42
animals (42) 42
leukemia, lymphocytic, chronic, b-cell - drug therapy (40) 40
cell line, tumor (38) 38
leukemia (36) 36
phosphorylation (35) 35
metabolism (32) 32
hemic and lymphatic diseases (31) 31
vidarabine - analogs & derivatives (31) 31
leukemia, lymphocytic, chronic, b-cell - pathology (30) 30
leukemia, myeloid, acute - drug therapy (29) 29
tumor cells, cultured (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
cancer (27) 27
cells (27) 27
fludarabine (27) 27
pharmacology & pharmacy (27) 27
antineoplastic agents - therapeutic use (26) 26
dose-response relationship, drug (25) 25
leukemia, lymphocytic, chronic, b-cell - metabolism (25) 25
acute myelogenous leukemia (24) 24
therapy (24) 24
abridged index medicus (23) 23
ribonucleotide reductase (23) 23
cll (22) 22
cytarabine - administration & dosage (22) 22
mice (22) 22
expression (21) 21
treatment outcome (21) 21
deoxycytidine kinase (20) 20
in-vitro (20) 20
inhibition (20) 20
acute myeloid-leukemia (19) 19
drug administration schedule (19) 19
antineoplastic agents - pharmacokinetics (17) 17
human necessities (17) 17
hygiene (17) 17
leukemia, lymphocytic, chronic, b-cell - genetics (17) 17
medical or veterinary science (17) 17
multiple myeloma (17) 17
phase-i (17) 17
preparations for medical, dental, or toilet purposes (17) 17
rna, messenger - genetics (17) 17
vidarabine - administration & dosage (17) 17
clofarabine (16) 16
transcription (16) 16
antineoplastic agents - administration & dosage (15) 15
child (15) 15
chronic lymphocytic leukemia (15) 15
cytarabine (15) 15
multiple myeloma - drug therapy (15) 15
protein kinase inhibitors - pharmacology (15) 15
signal transduction (15) 15
survival (15) 15
time factors (15) 15
activation (14) 14
adenosine triphosphate - metabolism (14) 14
adolescent (14) 14
antineoplastic agents - chemistry (14) 14
arabinonucleosides - administration & dosage (14) 14
flow cytometry (14) 14
hematology, oncology and palliative medicine (14) 14
inhibitor (14) 14
mechanism (14) 14
multiple myeloma - metabolism (14) 14
multiple myeloma - pathology (14) 14
neoplasms - drug therapy (14) 14
nucleoside analogs (14) 14
prognosis (14) 14
1-beta-d-arabinofuranosylcytosine 5'-triphosphate (13) 13
aged, 80 and over (13) 13
arabinonucleosides - pharmacokinetics (13) 13
cell cycle - drug effects (13) 13
chemotherapy (13) 13
deoxycytidine - analogs & derivatives (13) 13
infusions, intravenous (13) 13
pharmacokinetics (13) 13
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (13) 13
proteins (13) 13
proto-oncogene proteins c-bcl-2 - genetics (13) 13
research (13) 13
arabinonucleosides - therapeutic use (12) 12
cell proliferation - drug effects (12) 12
cell survival (12) 12
clinical trials as topic (12) 12
kinases (12) 12
proto-oncogene proteins c-bcl-2 - metabolism (12) 12
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pediatric Drugs, ISSN 1174-5878, 2005, Volume 7, Issue 4, pp. 265 - 266
Journal Article
Pediatric Drugs, ISSN 1174-5878, 07/2005, Volume 7, Issue 4, p. 266
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 09/2017, Volume 58, Issue 9, pp. 2026 - 2039
The approval of venetoclax, a 'BH3-mimetic' antagonist of the BCL-2 anti-apoptotic protein, for chronic lymphocytic leukemia represents a major milestone in... 
BCL-2 | rational combinations | BCL-XL | MCL-1 | Venetoclax | resistance | BCL-X-L | OVERCOMES ABT-737 RESISTANCE | ACUTE MYELOGENOUS LEUKEMIA | ACUTE MYELOID-LEUKEMIA | DEPENDENT KINASE INHIBITOR | SMALL-MOLECULE INHIBITOR | BRUTON TYROSINE KINASE | ONCOLOGY | CHRONIC LYMPHOCYTIC-LEUKEMIA | BH3 MIMETIC ABT-199 | HEMATOLOGY | FOLLICULAR LYMPHOMA-CELLS | Neoplasms - metabolism | Apoptosis - drug effects | Humans | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | bcl-X Protein - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Apoptosis - genetics | Peptide Fragments - pharmacology | Antineoplastic Agents - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Proto-Oncogene Proteins c-bcl-2 - metabolism | Biomimetics | Neoplasms - genetics | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | bcl-X Protein - antagonists & inhibitors | Proto-Oncogene Proteins - therapeutic use | Proto-Oncogene Proteins c-bcl-2 - chemistry | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins - pharmacology | Myeloid Cell Leukemia Sequence 1 Protein - antagonists & inhibitors | Clinical Trials as Topic | Sulfonamides - pharmacology | Drug Discovery | Myeloid Cell Leukemia Sequence 1 Protein - genetics | Neoplasms - drug therapy | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Peptide Fragments - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | bcl-X Protein - metabolism
Journal Article
F1000Research, ISSN 2046-1402, 2017, Volume 6, p. 1924
Journal Article
Cancer Research, ISSN 0008-5472, 01/2017, Volume 77, Issue 2, pp. 234 - 237
In 2016, Tata Memorial Center in Mumbai, India, reached its platinum jubilee milestone (75 years), which was celebrated with conferences. The first of these... 
ONCOLOGY | Health Resources - utilization | Medical Oncology - methods | Neoplasms - therapy | Research Design | Humans | Medical Oncology - trends | Medical research | Platinum | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 14, pp. 3734 - 3743
Purpose: Ibrutinib inhibits Bruton tyrosine kinase (BTK) by irreversibly binding to the Cys-481 residue in the enzyme. However, ibrutinib also inhibits several... 
B-CELLS | ACTIVATION | ONCOLOGY | INITIAL THERAPY | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | PCI-32765 | RECEPTOR | OPEN-LABEL | SRC FAMILY KINASES | EXPRESSION | Humans | Pyrazines - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Benzamides - administration & dosage | Protein-Tyrosine Kinases - genetics | T-Lymphocytes - drug effects | Caspase 3 - genetics | Benzamides - adverse effects | Pyrazoles - adverse effects | Pyrimidines - administration & dosage | src-Family Kinases - antagonists & inhibitors | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Pyrazoles - administration & dosage | Signal Transduction - drug effects | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - adverse effects | Pyrimidines - adverse effects | Cell Line, Tumor | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Poly (ADP-Ribose) Polymerase-1 - genetics | Protein-Tyrosine Kinases - antagonists & inhibitors | Drugs | Phosphorylation | Leukocyte migration | Downstream effects | Leukemia | Carbon tetrachloride | Homology | Lymphocytes T | Kinases | Caspase-3 | Biological effects | Lymphocytes | Protein-tyrosine kinase | Downstream | Tyrosine | Chronic lymphatic leukemia | Extracellular signal-regulated kinase | Caspase | Poly(ADP-ribose) polymerase | CCL3 protein | Lymphatic leukemia | CCL4 protein | Patients | Bruton's tyrosine kinase | Signaling | Inhibitors | Experimental design | Cell death | Cell migration | Chemokines | Cancer | ibrutinib | apoptosis | Bruton tyrosine kinase | chronic lymphocytic leukemia | acalabrutinib
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2019, Volume 380, Issue 22, pp. 2095 - 2103
Journal Article
Journal Article
Blood, ISSN 0006-4971, 09/2010, Volume 116, Issue 12, pp. 1999 - 2000
Journal Article